Recent Advances in Biotechnology

Volume: 3

Recent Progress in Glycotherapy

Indexed in: EBSCO.

Carbohydrates (monosaccharides, oligosaccharides and polysaccharides) exist naturally in free from and as components of other macromolecules (nucleic acids, proteins and lipids). Glycotherapy refers ...
[view complete introduction]


Back


Vaccine and Antibody Therapy Against Thomsen- Friedenreich Tumor-Associated Carbohydrate Antigens

Pp. 3-38 (36)

DOI: 10.2174/9781681083919116030004

Author(s): Paula A. Videira, Sylvain Julien, Liliana R. Loureiro, Diana P. Sousa, Mylène A. Carrascal, Philippe Delannoy

Abstract

The Thomsen Friedenreich (TF) carbohydrate antigens are a group of short O-glycans overexpressed on most carcinomas that have been correlated with cancer progression and poor prognosis. Usually associated with immunosuppressive tumor environment, there is a number of potential immunotherapeutics against TF antigens have been developed, which comprise vaccines and antibodies. As therapeutic vaccination, TF antigens already entered into clinical trials, but with limited success due to low patient’s response. Novel vaccine design, with multiantigenicity and pointing towards the cellular immune responses arises as a potent stratagem to overcome the low ability of TF antigens to boost immune responses, typical of carbohydrates. The development of antibodies against TF antigens boosted even before vaccine development. These are mainly used for diagnostics, but so far no such antibody entered into clinical trials in patients. Increasing the specificity and the therapeutic efficiency of existing antibodies and developing novel antibodies are still necessary. The vast array of methodologies and engineering techniques available today will allow rapid development and novel formats for both vaccines and antibodies. Vaccines and antibodies targeting the same epitopes can function in synergy both to protect and to clear patient’s cancer cells. Whilst on one hand, TF antigens dampen immune responses against tumor cells, it is anticipated that the challenge is overcome by applying our increasing knowledge of the mechanisms behind to improve molecular design. Novel solutions are also envisaged by combining anti-TF therapies with other immunotherapies.

Keywords:

Clinical trials, Glycan-based vaccines, IgG, Immune response, Immunological memory, Immunotherapy, Mimetic vaccines, Monoclonal antibodies, Mucins, O-glycans, Self-adjuvanting vaccines, Sialic acid, Sialyl-Tn antigens, T antigen, Therapeutic antibodies, Theratope, Thomsen Friedenreich antigens, Tn antigen, Tumor associated carbohydrates.